Rigel Pharmaceuticals

$1.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
+$0.01 (0.61%) As of 4:33 PM EDT after-hours

Why Robinhood?

You can buy or sell RIGL and other stocks, options, ETFs, and crypto commission-free!

About RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. Read More The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Employees
158
Headquarters
South San Francisco, California
Founded
1996
Market Cap
276.55M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.76M
High Today
$1.72
Low Today
$1.62
Open Price
$1.68
Volume
1.62M
52 Week High
$3.64
52 Week Low
$1.60

Collections

RIGL Earnings

-$0.18
-$0.11
-$0.04
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.